Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPA trial in untreated metastatic pancreatic adenocarcinoma
2022-004154-63Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valproic acid, simvastatin, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression-free survival. Started Jan 2023; status: active.
02
Drugs
valproic acidsimvastatingemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2022-004154-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004154-63.